source
- Sanofi eyes 'moonshot' drug acquisitions to offset upcoming Dupixent patent lossSanofi's CFO Francois-Xavier Roger told Fierce that the company is looking at 'moonshot' treatments as potential acquisition targets to rebuild its pipeline. The push comes as the U.S. patent on D…
- AstraZeneca launches $1.5 billion cost-saving plan to fund growth, says no layoffs expectedAstraZeneca announced a three-year cost‑saving initiative worth $1.5 billion during its third‑quarter earnings call. The program, called Reshaping for Sustainable Growth, aims to redeploy resource…